The improved product is aimed at pharmaceutical and biotechnology researchers to allow them to import and analyze their own Affymetrix GeneChip array data and annotate their samples.
It includes tools for correlating gene expression with clinical attributes, identifying genes associated with disease, prioritizing pathway and target analysis by comparing gene expression differences between normal and diseased tissue samples and integrating typical analysis tools with new algorithms and visualization tools.
Our customers seek to understand expression data as they relate to donor information and conventional pathology parameters, said Dennis Rossi, senior vice president for genomics at Gene Logic. Users of Genesis 2.5 have the opportunity to potentially identify surrogate biomarkers and increase their insight into mechanism of action and disease progression.
